SOURCE: Aoxing Pharmaceutical Co., Inc.

May 24, 2010 11:57 ET

Aoxing Pharmaceutical Company to Present at UBS Global Specialty Pharmaceuticals Conference 2010

NEW YORK, NY--(Marketwire - May 24, 2010) -  Aoxing Pharmaceutical Company, Inc. (NYSE Amex: AXN) ("Aoxing Pharma"), a specialty pharmaceutical company focusing on research, development, manufacturing and distribution of narcotic and pain-management products, today announced that the Company will be presenting at the UBS Global Specialty Pharmaceuticals Conference at 11:30 AM BST on June 3, 2010 in London.

Mr. Zhenjiang Yue, CEO, and Dr. David Shao, CFO, will provide a review of recent pipeline developments, international collaborations and financial progress at Aoxing Pharma. 

A live webcast and 30-day archive of the presentation will be available at:
http://cc.talkpoint.com/ubsx001/060210a_ke/?entity=5_YF7LM2K

About Aoxing Pharmaceutical Company, Inc.

Aoxing Pharmaceutical Company, Inc is a US incorporated specialty pharmaceutical company with its main operations in China, specializing in research, development, manufacturing and distribution of a variety of narcotics and pain-management products. Headquartered in Shijiazhuang City, outside Beijing, Aoxing has the largest and most advanced manufacturing facility for highly regulated narcotic medicines. Its facility is one of the few GMP facilities licensed for the manufacture of narcotic medicines by the China State Food and Drug Administration (SFDA). It has joint venture collaboration with Johnson Matthey Plc to produce and market narcotics and neurological drugs in China. It also has strategic alliance partnership with QRxPharma and American Oriental Bioengineering, Inc. For more information, please visit: www.aoxingpharma.com.

Safe Harbor Statement from Aoxing Pharmaceutical Company, Inc.

Statements made in this press release are forward-looking and are made pursuant to the safe harbor provisions of the Securities Litigation Reform Act of 1995. Such statements involve risks and uncertainties that may cause actual results to differ materially from those set forth in these statements. The economic, competitive, governmental, technological and other risk factors identified in the Company's filings with the Securities and Exchange Commission, including the Form 10-K for the year ended June 30, 2009, may cause actual results or events to differ materially from those described in the forward looking statements in this press release. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether because of new information, future events, or otherwise.

Contact Information

  • Investor Relations Contact:
    Brian Korb
    Vice President
    The Troup Group LLC
    Tel: +1 646 378 2923
    Email: bkorb@troutgroup.com